Opinion

Video

Managing AEs With Osimertinib

Author(s):

Heather A. Wakelee, MD, FASCO,Roy S. Herbst, MD, PhD

Panelists discuss how managing adverse events (AEs) with osimertinib requires proactive monitoring and intervention, with monotherapy generally being well-tolerated aside from common AEs like rash and diarrhea.

Video content above is prompted by the following:

  • What has been your experience managing AEs from osimertinib in both monotherapy and combination settings?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity
View More
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas
Video

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

May 1st 2025 - Jun 6th 2025

online-activity
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

May 1st 2025 - May 2nd 2026

online-activity
View More
Related Content